AbbVie isn’t losing its control of its biggest cash cow Humira (adalimumab) quite yet, despite the influx of eight adalimumab biosimilars vying for market share, according to a new report from Samsung Bioepis.
The quarterly biosimilar market report, released Tuesday, found that despite the launch of…
Click here to view original post
